Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Cardiac Syndrome Clear all
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

NCT00809965
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
Interventions
Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Placebo, Standard of care
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
15,526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
73
States / cities
Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention

NCT01522417
View directory record Official record
Conditions
Myocardial Infarction, Acute Coronary Syndromes, Unstable Angina
Interventions
Short Tirofiban, Eptifibatide, Long Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
13
States / cities
Kissimmee, Florida • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 2, 2026, 7:10 AM EDT
Withdrawn Phase 4 Interventional

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

NCT02048085
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Medical Center of South Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
El Dorado, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

NCT01004406
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 2, 2026, 7:10 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Hormones Inflammation and Thrombosis

NCT01875185
View directory record Official record
Conditions
Acute Coronary Syndrome, Thrombosis
Interventions
Aspirin 81 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 2, 2026, 7:10 AM EDT
Not listed No phase listed Observational

VITROS Immunodiagnostic Products hs Troponin I

NCT03581578
View directory record Official record
Conditions
Acute Coronary Syndrome (ACS), Myocardial Infarction
Interventions
Not listed
Lead sponsor
Ortho-Clinical Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Montgomery, Alabama • Chandler, Arizona • New Haven, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

Positive Psychology for Acute Coronary Syndrome Patients

NCT03122184
View directory record Official record
Conditions
ACS - Acute Coronary Syndrome
Interventions
Positive Psychology + Motivational Interviewing, Motivational Interviewing Health Education
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 2, 2026, 7:10 AM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

NCT04175626
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions
Orsiro DES
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
33
States / cities
Fairhope, Alabama • Concord, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Not applicable Interventional Results available

COPES Phase I Randomized Controlled Trial of Treatment For Distress in Heart Disease Patients

NCT00158054
View directory record Official record
Conditions
Heart Diseases, Depression
Interventions
Enhanced depression care, Referred depression care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
21 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 2, 2026, 7:10 AM EDT
Completed No phase listed Observational

Predicting the Development of Myocardial Depression in Acute Neurological Patients

NCT03801694
View directory record Official record
Conditions
Myocardial Depression, Takotsubo Syndrome, Subarachnoid Hemorrhage, Acute Ischemic Stroke
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 2, 2026, 7:10 AM EDT
Terminated Phase 3 Interventional Results available

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

NCT00385138
View directory record Official record
Conditions
Atherosclerosis, Acute Coronary Syndrome (ACS)
Interventions
Cangrelor, clopidogrel, Placebo bolus & placebo infusion, Placebo capsules - end of PCI, Placebo capsules - end of infusion
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
5,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

NCT00736229
View directory record Official record
Conditions
Hyperglycemia, Acute Coronary Syndromes, Myocardial Infarction
Interventions
Exenatide
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 2, 2026, 7:10 AM EDT
Terminated Phase 2 Interventional Results available

MT1002 Phase II Study in ACS Patients With PCI

NCT04723186
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
MT1002 for Injection
Drug
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Industry
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Muncie, Indiana
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 2, 2026, 7:10 AM EDT
Not listed No phase listed Observational

Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology

NCT01316159
View directory record Official record
Conditions
Coronary Atherosclerosis, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Endothelial Shear Stress, Arterial Remodeling
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2011 · Synced Oct 2, 2026, 7:10 AM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS

NCT02415803
View directory record Official record
Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
low-dose ticagrelor, conventional-dose ticagrelor, Clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 2, 2026, 7:10 AM EDT
Active, not recruiting No phase listed Observational

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

NCT03440697
View directory record Official record
Conditions
Aortopathies, Thoracic Aortic Aneurysm, Aortic Valve Disease, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Ascending Aortic Disease, Descending Aortic Disease, Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Marfan Syndrome, Loeys-Dietz Syndrome, Vascular Ehlers-Danlos Syndrome, Shprintzen-Goldberg Syndrome, Turner Syndrome, PHACE Syndrome, Autosomal Recessive Cutis Laxa, Congenital Contractural Arachnodactyly, Arterial Tortuosity Syndrome, Bicuspid Aortic Valve-Associated Aortopathy, Bicuspid Aortic Valve, Familial Thoracic Aortic Aneurysm and Aortic Dissection
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 2, 2026, 7:10 AM EDT
Withdrawn Phase 2 Interventional

Dobutamaine Versus Milrinone in Cardiorenal Syndrome

NCT02644057
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
Milrinone, Dobutamine
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 2, 2026, 7:10 AM EDT
Terminated Not applicable Interventional Results available

The Reducing Exercise Sensitivity With Exposure Training (RESET) Study

NCT05099926
View directory record Official record
Conditions
Acute Coronary Syndrome, Fear Anxiety, Physical Inactivity
Interventions
Reducing Exercise Sensitivity with Exposure Training
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578
View directory record Official record
Conditions
Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Investigative Site, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 2, 2026, 7:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate）and Plavix® in Healthy Participants

NCT07619885
View directory record Official record
Conditions
Acute Coronary Syndromes (ACS), Recent Myocardial Infarction, Recent Stroke, Peripheral Arterial Disease
Interventions
CG-0255 Besylate for Injection, CG-0255 Besylate Capsule, Clopidogrel
Drug
Lead sponsor
Shanghai CureGene Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Polypill in Acute Coronary Syndrome

NCT05514938
View directory record Official record
Conditions
Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
Interventions
Polypill, Usual Care (individual medications prescribed by primary cardiologist)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 7:10 AM EDT
Terminated No phase listed Observational

The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study

NCT02735720
View directory record Official record
Conditions
Thoracic Aortic Aneurysm
Interventions
TEVAR, Non-TEVAR medical treatment
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 2, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Tailored Antiplatelet Therapy Following PCI

NCT01742117
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 2, 2026, 7:10 AM EDT